This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OHRP OHR Pharmaceutical (OHRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About OHR Pharmaceutical Stock (NASDAQ:OHRP) 30 days 90 days 365 days Advanced Chart Get OHR Pharmaceutical alerts:Sign Up Key Stats Today's Range N/A50-Day Range$5.39▼$9.0752-Week Range N/AVolumeN/AAverage Volume180,228 shsMarket Capitalization$1.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Read More Receive OHRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OHR Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OHRP Stock News HeadlinesPharmaceutical StocksApril 14, 2024 | benzinga.comCYCC Cyclacel Pharmaceuticals, Inc.March 17, 2024 | seekingalpha.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)OHR Pharmaceutical (OHRP) is now in Oversold TerritorySeptember 12, 2021 | ca.finance.yahoo.comSee More Headlines OHRP Stock Analysis - Frequently Asked Questions How were OHR Pharmaceutical's earnings last quarter? OHR Pharmaceutical Inc (NASDAQ:OHRP) posted its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. When did OHR Pharmaceutical's stock split? Shares of OHR Pharmaceutical reverse split on Monday, February 4th 2019.The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OHR Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), IVERIC bio (OPHT), Cytori Therapeutics (CYTX), Novavax (NVAX), Immunomedics (IMMU) and Synergy Pharmaceuticals (SGYP). Company Calendar Last Earnings8/14/2018Today8/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OHRP CIK1173281 Webwww.ohrpharmaceutical.com Phone212-682-8452FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.46% Return on Assets-71.18% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.86 per share Price / BookN/AMiscellaneous Outstanding Shares2,829,000Free FloatN/AMarket Cap$1.08 million OptionableNot Optionable Beta0.84 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:OHRP) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OHR Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OHR Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.